Compare
Standard Biotools Inc. vs ADC Therapeutics SA vs Eton Pharmaceuticals, Inc. vs Siga Technologies Inc
| Latest fiscal year | Standard Biotools Inc. LAB | ADC Therapeutics SA ADCT | Eton Pharmaceuticals, Inc. ETON | Siga Technologies Inc SIGA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $85.33M | $81.36M | $79.95M | $94.57M |
| Revenue growth (YoY) | -6.2% | +14.9% | +104.9% | -31.8% |
| Gross margin | 49.9% | 92.9% (computed) | 53.5% | 68.6% (computed) |
| Operating margin | -129.2% | -149.3% | -1.1% | 25.1% |
| Net margin | -87.8% | -175.3% | -5.8% | 24.6% |
| Net income | -$74.90M | -$142.62M | -$4.60M | $23.28M |
| EPS (Diluted) | -$0.20 | -$1.12 | n/a | $0.32 |
| Operating cash flow | -$74.34M | -$141.17M | $10.52M | $43.47M |
| Free cash flow | -$82.65M | -$141.44M | $10.19M | n/a |
| Cash & equivalents | $120.86M | $261.34M | $25.94M | $154.97M |
| Total assets | $567.75M | $323.15M | $92.11M | $219.47M |
| Total liabilities | $143.46M | $508.98M | $65.96M | $20.65M |
| Shareholders' equity | $424.29M | -$185.83M | $26.15M | $198.82M |
| Return on year-end equity | -17.7% | n/a | -17.6% | 11.7% |
| Shares outstanding | 386.38M | 125.75M | 27.05M | 71.61M |
Revenue, most recent five fiscal years
| Fiscal year | Standard Biotools Inc. | ADC Therapeutics SA | Eton Pharmaceuticals, Inc. | Siga Technologies Inc |
|---|---|---|---|---|
| Latest | $85.33M Ended 2025-12-31 | $81.36M Ended 2025-12-31 | $79.95M Ended 2025-12-31 | $94.57M Ended 2025-12-31 |
| 1 year earlier | $91.01M Ended 2024-12-31 | $70.84M Ended 2024-12-31 | $39.01M Ended 2024-12-31 | $138.72M Ended 2024-12-31 |
| 2 years earlier | $106.34M Ended 2023-12-31 | $69.56M Ended 2023-12-31 | $31.64M Ended 2023-12-31 | $139.92M Ended 2023-12-31 |
| 3 years earlier | $97.95M Ended 2022-12-31 | $209.91M Ended 2022-12-31 | $21.25M Ended 2022-12-31 | $110.78M Ended 2022-12-31 |
| 4 years earlier | $130.58M Ended 2021-12-31 | n/a | $21.83M Ended 2021-12-31 | $133.67M Ended 2021-12-31 |